Skip to content
etf.net

Launched · SEC filings

Tema Oncology ETF

CANCNasdaqTemaD

$41.67−0.62 (−1.46%)

At close: Nov 2, 2026, 4:00 PM ET

D30/ 100

Rank 17 of 17 in Biotech & Genomics

D30/100Rank 17 of 17inBiotech & Genomics
Intraday session: down, 79 prints from 42.29 to 41.67. Range 41.49 to 42.28. Use the arrow keys to read each point.41.8042.0042.2010 AM12 PM2 PM4 PM
Expense ratio
0.75%*
Fund size
$216M
1Y total return
+36.6%
Yield · Last 12 months
0.05%
Holdings
57
Avg volume · 30D
31.3K sh
52W range
low $30.14high $47.00
Launched
Filings
SEC EDGAR

*After a fee waiver that ends Jun 28, 2027. Without it: 0.99%.

The ETF.net CANC Grade

Based on 5 of 6 pillars

D

Score 30 out of 100

Category
Biotech & Genomics⁠
Rank
17 of 17
Six-pillar profile for CANC. Scores out of 100: Cost 3, Risk 61, Mission not scored, Tradability 28, Holdings 66, Durability 43. Strongest: Holdings (66). Weakest: Cost (3). Based on 5 of 6 pillars.

Score 30 of 100 falls in the D band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    F3 out of 100
    Rank 16 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    B61 out of 100
    Rank 9 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    D28 out of 100
    Rank 13 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    B66 out of 100
    Rank 7 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    C43 out of 100
    Rank 12 of 17

Our read on CANC

ETF.net Research

In short

DMost biotech funds buy the whole lab. CANC buys the cancer wing: an actively managed book of roughly 60 companies, with at least 80% of assets in firms that earn half their revenue or more from oncology.

Stated mandate

The Fund seeks long-term growth. Its principal strategy invests at least 80% of net assets in publicly listed companies deriving at least 50% of revenue from oncology.

Why people hold it

  • The 50%-of-revenue test is the whole point. It screens for companies where cancer is the business, not a side project, then builds roughly 60 names around that.
  • No oncology index to hug. A stock-picking team sets the portfolio, and the fund reports its results against the S&P 500 Total Return Index.stockanalysis.com
  • Running since 2023, with a global mandate: the book can reach across US and European cancer franchises rather than stopping at the US border.stockanalysis.com

Worth knowing

  • Costs 0.75% net of a waiver through June 28, 2027, versus 0.99% gross, and above the category median. Index peers IBBQ (0.19%) and XBI (0.35%) ask less.
  • A small fund that trades thinly, so spreads can be wider and order size matters more than with the largest biotech baskets.
  • Concentration cuts both ways: trial readouts, pricing policy and regulatory decisions in one disease area move this book. Distributions come annually or semiannually.

CANC Performance

Launched Aug 14, 2023

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.
CANC$13,658
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. CANC $13,658. SPY $11,199. Use the arrow keys to read each point.$10,000$12,000$14,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for CANC. Periods over one year show the average yearly return.
PeriodCANC
Year to date+21.8%
1 month+0.7%
3 months+4.2%
1 year+36.6%
3 yearsper year+25.7%
5 yearsFund is under 5 years oldper yearNo data
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for CANC
YearReturn barCANC
2026 YTD+21.8%
2025+42.9%
2024−5.4%
2023+8.5%

History from Aug 17, 2023

CANC in the news

CANC Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
0.05%Last 12 months
Payout per share
$0.02Last 12 months
Last payment
$0.02 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2023–2026

One bar per payment. 3 payments from 2023 to 2026 YTD. Dec 13, 2023 $0.15; Dec 11, 2024 $0.73; Dec 10, 2025 $0.02. Use the arrow keys to read each point.2023202420252026YTD
Ex-datePay dateAmount per share
Dec 10, 2025Dec 11, 2025$0.02
Dec 11, 2024Dec 12, 2024$0.73
Dec 13, 2023Dec 15, 2023$0.15

$10,000 in CANC 3 years ago paid $386 in dividends.

CANC Risk

Risk pillarB61 out of 100Rank 9 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
18.8%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
1.08
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−28.0%
38 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.72
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

CANC Cost

Compare CANC and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$10,530

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • CANC 0.75%

    $14,482

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • CANC 0.75%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$5K$10K$15K051015202530CANC $14,482IBBQ $3,952

Year by year

YearCANCIBBQOverpaying
10$1,336$347$989
20$5,078$1,351$3,727
30$14,482$3,952$10,530
How the 0.75% is worked out

Full fee 0.99%− waiver 0.24%= you pay 0.75%

The waiver ends Jun 28, 2027. After that the fee is 0.99% unless Tema renews it. Source: prospectus, Jun 2026.

Other funds in Biotech & Genomics

See others